Reportlinker Adds Global Contraceptives Industry

NEW YORK, Nov. 17, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Contraceptives Industry

http://www.reportlinker.com/p087292/Global-Contraceptives-Industry.html

This report analyzes the worldwide markets for Contraceptives in US$ Million by the following product segments: Oral Contraceptives, Condoms, Implants/ Injections, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 164 companies including many key and niche players such as Ansell Limited, Bayer Schering Pharma AG, Church & Dwight Co. Inc., Conceptus, Inc., Condomi Health International GmbH, Female Health Company, Fuji Latex Co Ltd., Johnson & Johnson, Ortho-McNeil-Janssen Pharmaceutical Inc., Merck & Co., Inc., Okamoto Industries, Inc., SSL International PLC, Teva Pharmaceutical Industries Limited, Warner Chilcott, Pfizer Inc., and Wyeth Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CONTRACEPTIVES MCP-2528

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 2

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

Oral Contraceptives 3

Condoms 4

Implants/Injections 4

Other Contraceptives 4

2. INDUSTRY OVERVIEW 5

A Primer 5

Table 1: World Contraceptive Use (2007): Percentage Share of

Women in the Age Group of 15 to 49 Years Utilizing

Contraceptives - Breakdown by Region and Type of

Contraceptive Method 6

Table 2: Global Female Contraceptive Market (2007):

Percentage Market Share Breakdown of Leading Players - Bayer,

Johnson & Johnson, Schering-Plough, Barr Pharmaceuticals,

Wyeth Laboratories, and Others (includes corresponding

Graph/Chart) 6

Table 3: Global Contraceptive Market: Percentage Share

Breakdown of Leading Brands by Number of New Prescriptions

(NRX) for the Month of January & June 2008 and January 2009

(includes corresponding Graph/Chart) 7

Impact of Recession: An Unequivocal Review 7

Cooling Economy Induces Changes in Childbearing Trends 7

Recession Adds Fuel to Cost/Affordability Challenge 8

Rising Preference for Surgical Family Planning Procedures 8

Outlook 8

Other Trends & Issues 9

Increasing Awareness Over STDs to Create Additional Demand

for Condoms 9

HIV Prevalence and Incidence Statistics 9

Table 4: Global Prevalence of HIV Infection by Region (2007

& 2008) in Millions (includes corresponding Graph/Chart) 10

Table 5: HIV Prevalence in Select Countries (2007) 11

Multifunctional Modern Contraceptives Make a Foray 12

Skin Sprays: A Novel Way of Contraception 12

Extensive Distribution Drives growth of Contraceptive Products 12

Public Health Organizations Spur Condoms Use 13

USAID Worldwide Shipments of Condoms and Other Contraceptives 13

Table 6: USAID Shipments of Condom and Other Contraceptives

Worldwide (2008): Percentage Value Share Breakdown by Region

-Africa, Asia/Near East, Latin America/the Caribbean,

Europe/Eurasia, and Middle East (includes corresponding

Graph/Chart) 14

Advertising for Contraceptives Acquires A Whole New Dimension 14

Manufacturers & Retailers Work in Sync to Accelerate Sales 14

Innovation Keeps the Fire Burning for the Condoms Market 15

Generic & Biosimilar Contraceptive Products Gain Ground 15

Generics Manufacturers 15

OTC Hormonal Contraceptives - An Attractive Market 16

R&D Companies & Generic Manufacturers - Developing Countries 16

Commercial Success of R&D Brands Sustain Developmental

Programs in Developing Countries 17

Challenges Facing Generic Contraceptive Products Manufacturers 17

3. PRODUCT OVERVIEW 18

Types of Contraception 18

The Contraceptive Timeline 18

Table 7: World Contraceptive Prevalence (2005): Percentage

Use of Select Contraception Methods In Less Developed and

Developed Regions - Traditional Method, Pill, IUD, Condom,

Implant/Injectables, Male Sterilization, Female

Sterilization (includes corresponding Graph/Chart) 19

Classification 19

By Function 19

Barrier Contraceptives 19

Characteristic Features of Barrier Methods 20

Hormonal Contraceptives 20

Prescription Contraceptives 20

Oral Contraceptives 20

Overview of Oral Contraceptives - Benefits vs. Risks 21

Usage Levels of OCs in Worldwide Scenario 21

Table 8: Percentage of Women in the age group 15-49 using

contraception across select regions and countries for the

years 2005 and 2006 22

Traditional and Modern 22

Reversible and Permanent 23

Birth Control Methods and their Use in Major Regions

Worldwide 23

Contraception - Levels of Effectiveness 24

Effectiveness Index of Contraceptive Measures 24

Unmet Need for Contraception 26

Segmental Analysis 26

A. Condoms 26

Overview 26

Categories 26

Latex Condoms 26

Non-Latex Condoms 26

Skin Condoms 27

Polyurethane (PU) Condoms 27

Table 9: Leading Product Types in the US Condoms Market

(2005) - Percentage Share Breakdown for Latex,

Synthetic/Polyurethane and Natural (includes corresponding

Graph/Chart) 27

Comparison Between Polyurethane & Latex Condoms 27

Male Condom - Effectiveness of Protection Against STDs 28

Myths & Facts 28

Selection & Effective Use of Condoms 28

Condoms in the War Against AIDS 28

Highlights 29

Growth Factors 29

Factors Hindering Wide Spread Use of Condoms 30

Measures Aimed at Increasing Usage 30

Female Condoms 30

Who are the Main Users? 31

Reality - An Effective Female Condom 31

B. Oral Contraceptives (OCs)/Pills 31

A Peep into the Past 32

Synthetic Oral Contraceptives 32

Characteristic Features of Oral Contraceptives (OCs) 32

Top Brands/Manufacturers of Oral Contraceptive

Formulations Containing Levonorgestrel 0.15 MG/ Ethinyl

Estradiol 30 mcg 33

Table 10: Worldwide Hormonal Contraceptive Players

(2005)- Market Share Breakdown by Leading Players:

Schering AG, J&J, Barr, Wyeth, Watson, Akzo Nobel, and

Others (includes corresponding Graph/Chart) 34

Bayer Schering Pharma's "Yasmin": A Resounding Brand Worldwide 34

Table 11: Sales of Bayer Schering Pharma AG's Yasmin, and

Yaz for the Years 2007 and 2009 (In Euro Millions) 35

Advantages of Using Ocs 35

Effects of Long-Term Use of OCs 35

Use of OCs/Pills - Myths & Facts 36

Oral Contraceptives - Challenges & Strategies to Overcome

Problems 36

Factors Associated with Failure of OCs/Pills 37

Health Conditions to be Addressed when Using OCs 37

Understanding Risks Associated with Use of OCs 37

Cardiovascular Disease - A Major Side Effect of OCs 38

Intake of OCs Result in High Blood Pressure 38

Smoking Intensifies Respiratory Problems in Pill Users 38

Complications Arising by Use of OCs Directly Related to Age 38

Relation Between OC and Cancer 38

Depression Linked to Use of OCs 39

OCs Increases Osteoporosis Risk at Later Stage 39

OCs May Reduce Sex Drive 39

Effects of Pill on Childbearing Capacity 39

Visiting a Doctor - Highly Recommended in Case of Warning

Symptoms 40

Emergency Contraception (EC) - A New Face of OCs 40

Role of ECPs 40

Effectiveness of ECP 41

Different Types of EC Products 41

Mini Pills 41

RU486 - the French Abortion Pill 42

Top Brands/Manufacturers of Emergency Contraceptive Pills

Containing Levonorgestrel 0.75 mg 42

Top Brands/Manufacturers of Emergency Contraceptive Pills

Containing Levonorgestrel 0.25mg and Ethinyl Estradiol

50mcg 43

Availability of Hormonal Contraceptives as OTC Drugs 43

C. Injectable Contraceptives 43

Depo-Provera 43

Characteristic Features of Injectable Contraceptives 44

Injectables - Challenges & Strategies to Overcome Problems 44

Top Brands & Manufacturers of Two & Three Month Injectable

Contraceptive Formulations Containing Depot

Medroxyprogesterone Acetate (DMPA), and Norethisterone

Enanthate 45

Top Brands & Manufacturers of Monthly Injectable

Contraceptive Formulations Containing (Norethisterone

Enanthate 50 mg and Estradiol Valerate 5 mg), (Dihydroxy

Progesterone Acetophenide 75 mg and Estradiol Enanthate

5 mg), (Medroxyprogesterone Acetate 25 mg and Estradiol

Cypionate 5 mg), (Algeston acetophenide 150 mg and

Estradiol Enanthate 10 mg), and Hydroxiprogesterone

Caproate 250 mg 46

D. Intrauterine Devices (IUDs)/Implants 47

Product Categories 47

CopperT 380A (ParaGard) 47

Progesterone T (or Progestasert) 47

Characteristic Features 48

Benefits 48

Side Effects 48

Challenges & Strategies to Overcome Problems 49

Table 12: IUD Users Worldwide (2005): Percentage Breakdown

by Select Geographic Country/Region Geographic

Country/Region IUD Users (includes corresponding

Graph/Chart) 49

Long-term Reversible Contraceptive Implants 50

Products 50

Norplant 50

Implanon 50

Mirena 50

Characteristic Features of Implantable Contraceptives 51

Challenges & Strategies to Overcome Problems 51

E. Spermicides 52

Product Categories 52

Benefits 52

Drawbacks 52

Contraceptive Foam 52

Delfen Contraceptive Foam 52

Contraceptive Cream or Jelly 53

Encare Ovals 53

F. Diaphragms 53

G. Withdrawal & Douching 53

H. Sterilization 54

Tubal Ligation 54

Reasons Behind Adoption 55

Risk of Complications 55

Types 55

Abdominal Procedures 55

Laparoscopy 55

Mini-Laparotomy 56

Laparotomy 56

Vaginal Procedures 56

Culdoscopy 56

Colpotomy 56

Hysterectomy - A High Risk Surgery 56

Selective Tubal Occlusion Procedure (STOP) 56

Vasectomy 57

Method of Working 57

Reasons Behind Adoption 57

Risk of Complications 58

I. Other Contraceptive Methods 58

Contraceptive Sponges 58

Today Sponge 58

Characteristic Features of Today Sponge 59

Table 13: Efficiency Rates of Today Sponge Based on Usage

for 12-Month Period (includes corresponding Graph/Chart) 60

Allendale Pharmaceuticals 60

Protectaid Sponge 60

Characteristic Features of Protectaid Sponge 61

Cervical Caps 61

Pros and Cons of the Device 61

Vaginal Contraceptive Film (VCF) 62

Contraceptive Vaccine 62

Ortho Evra Weekly Contraceptive Patch 62

NuvaRing Monthly Vaginal Ring 63

4. RESEARCH AND DEVELOPMENT 64

Oral Contraceptive Minimizes Premenstrual Syndrome Symptoms as

per New Study 64

Cause of Infertility - Not Associated with IUDs 65

Presence of Estrogen in OCs Offers Protection from Colorectal

Cancer 65

Hormonal Contraceptive Usage & Risk Associated with Certain STDs 65

Use of Third Generation Ocs Increases Risk of Blood Clots 65

High Risk of Deep Vein Thrombosis with Cyproterone- Containing

OCs 66

5. ROLE OF UNITED NATIONS IN PROMOTING USE OF CONTRACEPTIVES 67

Female Condoms Reach New Heights with Aid from UNAIDS 67

Donor Support for Contraceptive Commodity 67

Table 14: Total Cost of Contraceptives and Condoms:

2000-2010E (In US$ Million) (includes corresponding

Graph/Chart) 67

Unmet Need 68

Table 15: Donor Support by Region: 2004 (includes

corresponding Graph/Chart) 68

Table 16: Contraceptive Donor Support for STI/HIV Prevention

by Agency: 1997-2004 (US$ 000) 68

Donor Support by Contraceptive Method 69

Table 17: Donor Support by Contraceptive Method: 2000-2004

(In Thousand Units) (includes corresponding Graph/Chart) 69

Table 18: Donor Support for Contraceptive Method by Agency:

2000-2004 (In US$ Mill) (includes corresponding Graph/Chart) 69

Donor Support by Top Ten Countries 70

Table 19: Major Donor Support Recipient Countries: 2004 (In

US$ Million) (includes corresponding Graph/Chart) 70

Table 20: Donor Support for Condoms and Other Contraceptive

Commodities: 1997-2004 (In terms of %) (includes

corresponding Graph/Chart) 70

Donor Funding For Male Condoms 71

Table 21: Donor Funding For Male Condoms: 2000- 2004

(includes corresponding Graph/Chart) 71

Table 22: Donor Funding For Male Condoms by Region: 2004

(includes corresponding Graph/Chart) 71

Table 23: Number of Male Condoms Supplied by Donors:

Region-Wise Breakup for year 2004 72

Table 24: Donor Support for Condoms (1995-2004): Number of

Condoms by Donor - USAID, UNFPA, BMZ/KfW, DFID, EU, DKT,

PSI, IPPF, MSI, Netherlands, SIDA, and Japan (In Thousand

Units) (includes corresponding Graph/Chart) 74

Table 25: Donor Funding for Condoms (1995-2004): Number of

Condoms by Donor - USAID, UNFPA, BMZ/KfW, DFID, EU, DKT,

PSI, IPPF, MSI, Netherlands, SIDA, and Japan (In US$ 000)

(includes corresponding Graph/Chart) 75

Table 26: Total Number of Female Condoms in Private and

Public Sectors: Region-wise Split from Years 1997 through

2004 (includes corresponding Graph/Chart) 76

Table 27: Percentage of Couples Using Condoms for Family

Planning (2005) by Region 76

Use of Modern Contraceptives Grows in Developing Regions 78

Table 28: Estimated Numbers of Contraceptive Users in

Developing Nations: 2000-2015 (In Millions) (includes

corresponding Graph/Chart) 79

Table 29: Comparative Study of Modern Contraception Methods

in Developing Regions (including India & China) and

Developing Regions (excluding India & China) - Percentage of

Married Women Using Oral Contraceptives, Female

Sterilization, and Intrauterine Devices (IUDs): Recent Past

Data for 2000 (includes corresponding Graph/Chart) 80

Difference in Usage of Oral contraceptives in Developed and

Developing World 80

Table 30: Oral Contraceptives Usage by Married and Sexually

Active Unmarried Women (Aged 15-49 years) in Developed

Regions including North America, Eastern Europe & Central

Asia, and Australia & New Zealand: Recent Past Data for 2000 80

Table 31: Oral Contraceptives Usage by Married and Sexually

Active Unmarried Women (Aged 15-49 years) in Developing

Regions including Asia, Near East & North Africa,

Sub-Saharan Africa, Pacific Rim, and Latin America &

Caribbean: Recent Past Data for 2000 81

Prevalence of Contraceptive Methods 81

Table 32: Increase in Contraceptive Usage by 2005 -

Percentage Share Growth by Asia, Latin America and Africa

(includes corresponding Graph/Chart) 81

Table 33: Worldwide Contraceptives Market: Estimated Number

of Users (2015 & 2025) - Asia, Latin America and Africa

(includes corresponding Graph/Chart) 82

Table 34: Worldwide Contraceptive Market: Prevalence Amongst

Women (2000-2025) - Percentage Share by Asia, Latin America

and Africa (includes corresponding Graph/Chart) 82

United Nations Population Fund (UNFPA) 82

UNFPA Gets Aid from Britain to Help Developing World 83

Rise in Cost of Providing Contraceptives 84

Future Trends Worldwide 84

6. NEW PRODUCT INTRODUCTIONS/ INNOVATIONS 85

HLL Lifecare to Launch Pan Flavored Condoms 85

Glenmark Generics Receives USFDA Approval for Norethindrone

Tablets 85

HLL Lifecare to Introduce Moods in Australian Markets 85

Organon Releases Contraceptive NuvaRing 85

HRA Pharma Unveils ellaOne 85

Bayer Introduces Qlaira New Oral Contraceptive 86

Durex Introduces Avanti Bare™ 86

Teva to Introduce Tri-Lo Sprintec 86

Teva Announces Launch of Topiramate Tablets 86

Duramed Releases LoSEASONIQUE 86

Uganda Health Marketing Group Rolls Out NewFem, A New

Contraceptive Pill 87

TTK LIG to Unveil Durex Jeans Condoms 87

Teva Pharmaceutical Industries Receives Approval for Plan B

One-Step Emergency Contraceptive 87

Cupid Limited to Unveil Cost-effective Female Condoms 87

Bayer Schering Pharma Launches Qlaira® 88

Watson Laboratories Secures USFDA Approval for Plan B OTC

Generics 88

Organon Launches Vaginal Contraceptive Ring 88

Bayer Schering Pharma Rolls Out Oral Contraceptive 88

Hindustan Latex Introduces New Contraceptive Pill 89

FHI and HLL Launch Aastha Condom 89

NATCO Launches World-Class Oral Contraceptive 89

Bayer Plans Launch of Mirena in Japan 89

7. RECENT INDUSTRY ACTIVITY 90

FHC Bags Order to Supply 3.5 Million FC2 Female Condoms for

2010 World Cup in South Africa 90

SSL Acquires Majority Stake in BLBV 90

Columbia Laboratories Inks Definitive Agreement with Watson

Pharmaceuticals 90

Piramal Healthcare Signs Definitive Agreement with Cipla 91

Watson Pharmaceuticals to Market HRA Pharma's Emergency

Contraceptive 91

Lupin to Establish Three New Production Facilities 91

Pfizer to Purchase Wyeth 91

Ansell Healthcare Signs Agreement with NYC Department of

Health and Mental Hygiene 92

Teva Pharmaceutical Industries' Yaz Receives FDA Approval 92

Teva Pharmaceutical Industries' Yaz Receives Marketing

Approval from FDA 92

Watson Pharmaceuticals, Warner Chilcott Collaborate for Femring 92

Watson Pharmaceuticals Inks Agreement with Warner Chilcott for

WC3026 93

Merck Merges with Schering-Plough 93

Vystar Inks Agreement with Centrotrade Minerals and Metals and

Centrotrade Deutschland 93

Mayer Laboratories Signs Agreement with Alvogen Group 94

Hypermarcas Acquires Inal 94

Sosei Inks Distribution Agreement with ASKA Pharmaceuticals 94

Sanofi-Aventis to Construct Plant in Brazil 94

Durex Chinese Plant Starts Production 94

Patheon Expands Toronto Plant 95

Female Health Co Receives FDA Approval for Cheaper Female Condom 95

Mylan and Famy Care Sign Strategic Alliance for Exploring the

US Oral Contraceptive Market 95

Starpharma Holdings Signs Full License Agreement with SSL

International Plc 96

SSL International to TakeOver Crest Condom Brand 96

Teva Pharmaceutical Industries Acquires Barr Pharmaceuticals 96

Duramed Pharmaceuticals' LoSEASONIQUE® Receives FDA Approval 97

Bayer Schering Pharma's Qlaira® Receives Decentralized Drug

Approval 97

Bayer and Barr Pharmaceuticals Sign Agreements 97

Female Health's FC2 Receives FDA Approval 98

Faes Farma Signs Agreement with Gruenenthal 98

'Female Health' Bags Order in Papua New Guinea 98

Mylan Enters into Alliance with Famy Care 98

Bayer Schering Pharma to Launch YAZ Oral Contraceptive 99

Wuhan Humanwell Hi-Tech Industry to Expand Pharmaceutical

Business 99

Watson Laboratories Receives FDA Approval 99

Organon Licenses Spray Technology from Acrux 99

BioSante Initiates Phase II Trials of Oral Contraceptives 100

YAZ® Receives FDA Approval for New Indication 100

Paladin Labs Receives Approval to Market SEASONALE® 100

ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Receives Two

FDA Approvals (USA) 100

Conceptus Receives FDA Approval for Third-Generation Essure ®

Procedure 101

Wyeth Receives FDA Approval for Lybrel ™ 101

NuvaRing® Completes European Authorization in 13 Countries 101

HLL Expands Promotion of Female Condom 101

ChrysCapital Gains Minority Stake in Mankind Pharma 102

7 Chemicals Inks Deal with Ferring Pharmaceuticals 102

Synova Acquires Allendale Pharmaceuticals and Global Rights to

Today Sponge 102

Ansell Pockets Blowtex 102

Bayer Merges with Berlex to Establish Bayer HealthCare

Pharmaceuticals 102

UNFPA Releases Pacific-Design Condoms 103

Wyeth Completes Acquisition of Wyeth K.K. Japan 103

Conceptus, Inc. to Acquire Conceptus SAS 103

Warner Chilcott Company Enters into a Supply Agreement with

Watson Pharma 103

SSL International Fully Acquires Qingdao London Durex Co Ltd 104

Bayer HealthCare Takes Over Marketing/Distribution Network of

Pharmonyx Ltd. 104

8. FOCUS ON SELECT PLAYERS 105

Ansell Limited (Australia) 105

Bayer Schering Pharma AG (Germany) 105

Church & Dwight Co., Inc. (US) 105

Conceptus Inc (US) 106

Condomi Health International GmbH (Germany) 106

Female Health Company (US) 106

Fuji Latex Co Ltd (Japan) 106

Johnson & Johnson (US) 107

Ortho-McNeil-Janssen Pharmaceutical Inc (US) 107

Merck & Co., Inc (USA) 108

Okamoto Industries Inc (Japan) 108

SSL International PLC (UK) 108

Teva Pharmaceutical Industries Limited (Israel) 108

Warner Chilcott (US) 109

Pfizer Inc (USA) 109

Wyeth Corporation (US) 109

9. GLOBAL MARKET PERSPECTIVE 111

Table 35: World Recent Past, Current & Future Analysis for

Contraceptives by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 111

Table 36: World Historic Review for Contraceptives by

Geographic Region - US, Canada, Japan, Europe, Asia- Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 112

Table 37: World 11-Year Perspective for Contraceptives by

Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 113

Table 38: World Recent Past, Current & Future Analysis for

Oral Contraceptives by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 114

Table 39: World Historic Review for Oral Contraceptives by

Geographic Region - US, Canada, Japan, Europe, Asia- Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 115

Table 40: World 11-Year Perspective for Oral Contraceptives by

Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 116

Table 41: World Recent Past, Current & Future Analysis for

Condoms by Geographic Region- US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 117

Table 42: World Historic Review for Condoms by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 118

Table 43: World 11-Year Perspective for Condoms by Geographic

Region- Percentage Breakdown of Dollar Sales for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 119

Table 44: World Recent Past, Current & Future Analysis for

Implants/Injections by Geographic Region- US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 120

Table 45: World Historic Review for Implants/Injections by

Geographic Region - US, Canada, Japan, Europe, Asia- Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 121

Table 46: World 11-Year Perspective for Implants/Injections by

Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 122

Table 47: World Recent Past, Current & Future Analysis for

Other Contraceptives by Geographic Region- US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 123

Table 48: World Historic Review for Other Contraceptives by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 124

Table 49: World 11-Year Perspective for Other Contraceptives

by Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 125

10. THE UNITED STATES 126

A. Market Analysis 126

Outlook 126

Restraints 126

Are Women's Reproductive Rights Getting Axed on the New

Health Care Bill? 126

Major Market Trends 127

Changing Consumer Demographics 127

Relentless Promotional Programs Drive Home the Point 128

Use of Intimacy Products on the Rise 128

Generics Ransack the Branded Market 128

Condoms - A 'Fun, Inviting and Pleasurable' Way to Healthy

Life and Lifestyle 129

Market Share Statistics 129

Table 50: US Market for Male Contraceptives: Percentage

Breakdown of Retail Dollar Sales of Key Players for the

Year Ended January 2007 (includes corresponding

Graph/Chart) 129

Table 51: US Market for Male Contraceptives: Breakdown of

Retail Unit Sales of Key Players for the Year Ended January

2007 (In 000 Units) 130

Table 52: US Market for Female Contraceptives: Percentage

Breakdown of Retail Dollar Sales of Key Players for the

Year Ended January 2007 (includes corresponding

Graph/Chart) 130

Table 53: US Market for Female Contraceptives: Percentage

Breakdown of Retail Unit Sales of Key Players for the Year

Ended January 2007 (includes corresponding Graph/Chart) 130

Table 54: US Market for Female Contraceptives: Percentage

Breakdown of Dollar Sales of Leading Brands for the Year

Ended March 2005 (includes corresponding Graph/Chart) 131

Table 55: US Condoms Market: Percentage Breakdown of Dollar

Sales by Product Type for the Year Ended January 2006

(includes corresponding Graph/Chart) 131

Noticeable Shift in Retail Marketing Techniques 131

Rising Use of Condoms Amongst Teenagers 132

Changing Attitudes and Perceptions Drive Market Sales 132

Pill Continues to be One of the Most Popular Forms of

Contraception 133

Oral Contraceptives and its Shades of Grey 133

Marketing Efforts Aimed at Influencing Female College Students 133

Condoms Continuing Canter 134

Drug Stores Remain the Choice for Contraceptive Needs 134

Trade Class Statistics 134

Oral Contraceptives - Unanimously the Choice of American Women 135

Table 56: Contraceptive Features Preferred by Women in US

(includes corresponding Graph/Chart) 135

Table 57: US Market for New Prescription (NRx) Oral

Contraceptive (Estrogen/ Progestogen-based) Drugs (2006):

Percentage Market Share Breakdown of Leading Players

(includes corresponding Graph/Chart) 136

Table 58: US Market for Prescription (Rx) Oral

Contraceptives: Percentage Market Share Breakdown of

Leading Players for the Year 2007 (includes corresponding

Graph/Chart) 136

Table 59: US Prescription Contraceptives Market: Percentage

Market Share Breakdown for Select Product Categories for

the Years 2007 (includes corresponding Graph/Chart) 136

Table 60: US Market for Prescription Extended Cycle Oral

Contraceptives: Percentage Market Share Breakdown for

Leading Brands for the Years 2007 (includes corresponding

Graph/Chart) 137

Health Facts 137

Rising Use of Oral Contraceptives 137

Abortion Control Drugs & Methods 138

Medical Abortion 138

a. Mifepristone - A Medical Breakthrough 138

b. Methotrexate 138

Expanding the Use & Availability of EC Drugs 138

Pharmacies Sell ECPs 139

Demographics 139

Facts and Figures 139

Sales of Contraceptives (Male & Female) - Family Planning

Category 139

Insurance Coverage for Contraceptives Still in Contest 140

Key Player 140

Watson Pharmaceuticals 140

B. Market Analytics 141

Table 61: US Recent Past, Current & Future Analysis for

Contraceptives by Product Segment- Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 141

Table 62: US Historic Review for Contraceptives by Product

Segment - Oral Contraceptives, Condoms, Implants/Injections

and Others Markets Segments Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2006 (includes corresponding Graph/Chart) 142

Table 63: US 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/ Injections and

Others Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 143

11. CANADA 144

A. Market Analysis 144

Scenario 144

Outlook 144

Condoms Market 144

Immucon Obtains US Patent for Male Contraceptive Technology 145

B. Market Analytics 145

Table 64: Canadian Recent Past, Current & Future Analysis

for Contraceptives by Product Segment- Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 145

Table 65: Canada Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 146

Table 66: Canadian 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales Oral

Contraceptives, Condoms, Implants/Injections and Others

Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 147

12. JAPAN 148

A. Market Analysis 148

Outlook 148

Market for Oral Contraceptives Yet to Take Off 148

Innovation Expected to Drive Sales 148

Major Issues and Trends 149

Domestic Products Dominate the Market 149

Health Care Institutions Remain Main Distribution Channels 149

Market Issues 149

Compulsory Labeling of Contraceptives 149

Late Approval for Use of OCs in Japan 149

Factors Hindering Widespread Use of OCs 150

Condoms Market 150

Key Player 150

Sagami Rubber Industries Co., Ltd 150

B. Market Analytics 151

Table 67: Japanese Recent Past, Current & Future Analysis

for Contraceptives by Product Segment- Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 151

Table 68: Japanese Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 152

Table 69: Japanese 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/Injections and Others

Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 153

13. EUROPE 154

A. Market Analysis 154

Outlook 154

Condoms Market 154

B. Market Analytics 155

Table 70: European Recent Past, Current & Future Analysis

for Contraceptives by Geographic Region - France, Germany,

Italy, UK, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 155

Table 71: European Historic Review for Contraceptives by

Contraceptives by Geographic Region - France, Germany,

Italy, UK, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 156

Table 72: European 11-Year Perspective for Contraceptives by

Geographic Region - Percentage Breakdown of Dollar Sales for

France, Germany, Italy, UK, Spain, Russia and Rest of Europe

Markets for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 157

Table 73: European Recent Past, Current & Future Analysis

for Contraceptives by Product Segment - Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 158

Table 74: European Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 159

Table 75: European 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/ Injections and

Others Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 160

13a. FRANCE 161

A. Market Analysis 161

Outlook 161

Condoms Market 161

B. Market Analytics 162

Table 76: French Recent Past, Current & Future Analysis for

Contraceptives by Product Segment- Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 162

Table 77: French Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 163

Table 78: French 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/ Injections and

Others Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 164

13b. GERMANY 165

A. Market Analysis 165

Outlook 165

German Women Record Highest Usage Rate of Contraceptive Pill 165

Condoms Market 165

Table 79: Leading Players in the German Condoms Market

(2005) - Percentage Share Breakdown by Sales Revenues -

Sico, Vizit and Others-A Historic Review (includes

corresponding Graph/Chart) 165

B. Market Analytics 166

Table 80: German Recent Past, Current & Future Analysis for

Contraceptives by Product Segment- Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 166

Table 81: German Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms, Implants/

Injections and Others Markets Segments Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 167

Table 82: German 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/ Injections and

Others Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 168

13c. ITALY 169

A. Market Analysis 169

Outlook 169

B. Market Analytics 169

Table 83: Italian Recent Past, Current & Future Analysis for

Contraceptives by Product Segment- Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 169

Table 84: Italian Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 170

Table 85: Italian 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/ Injections and

Others Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 171

13d. THE UNITED KINGDOM 172

A. Market Analysis 172

Outlook 172

Overview 172

Changing Societal Trends 172

Innovations: Need of the Hour 173

Table 86: Contraception Market in the United Kingdom:

Percentage of Women Aged 16-49 Years Using Select Methods

of Contraception As of the Year 2005-06 (includes

corresponding Graph/Chart) 173

Availability of Contraceptives 174

Contraceptive Injections 174

Emergency Contraception (EC) 174

Barrier Contraceptives 174

Major Trends and Issues 174

Hormone Based Products Overtake Barrier Products 174

Condoms Still Find Immense Favor in Britain 174

Value of Condoms Declines Even as Volume Sales Increases 175

Table 87: Leading Players in the UK Condoms Market (2005)

- Percentage Share Breakdown by Sales Revenues - Durex,

Contex and Others - A Historic Review (includes

corresponding Graph/Chart) 175

Role of Pharmacies in Improving Availability of Condoms and

EC Drugs 175

Regulatory Environment 175

CEN Standards 175

Advertising and Promotion 176

Hormone Based Contraceptives Restricted by Legislation 176

B. Market Analytics 176

Table 88: UK Recent Past, Current & Future Analysis for

Contraceptives by Product Segment - Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 176

Table 89: UK Historic Review for Contraceptives by Product

Segment - Oral Contraceptives, Condoms, Implants/Injections

and Others Markets Segments Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2006 (includes corresponding Graph/Chart) 177

Table 90: UK 11-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/Injections and Others

Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 178

13e. SPAIN 179

A. Market Analysis 179

Current & Future Analysis 179

Outlook 179

B. Market Analytics 180

Table 91: Spanish Recent Past, Current & Future Analysis for

Contraceptives by Product Segment- Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 180

Table 92: Spanish Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condom

To order this report:

Drug and Medication Industry: Global Contraceptives Industry

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker